UK roommate matchmaking service Flatmate attracts seed funding

UK-based Ideal Flatmate, a roommate matchmaking service, has secured seed funding, raising its total tally up to 500 million pounds. The investors included Steve Leach, founder of Bigmouthmedia and chairman of Fetch Media and David Pollock, founder of Greene & Co. PRESS RELEASE Monday 24th July: Ideal Flatmate, the UK’s first algorithm based flatmate matchmaker has closed its seed funding round, taking total investment into the platform up to £500k. The platform, designed in collaboration with Cambridge professors, is based on an algorithm similar to that of dating websites and prioritises how well matched prospective flat-sharers are in regards to personalities rather than just location and budget. Founders of Ideal Flatmate Tom Gatzen and Rob Imonikhe came up with the idea following years of becoming increasingly frustrated with the lack of options for finding flatmates, after searching through current listing websites. The additional funding will allow Ideal Flatmate
Continue reading "UK roommate matchmaking service Flatmate attracts seed funding"

Nyotron takes in $21 mln

Santa Clara, California-based Nyotron, a cyber security company, has raised $21 million in funding. DGB Investments led the round with participation from other investors that included Mitvah Shamir, Gil Agmon and Shmuel Harlap. PRESS RELEASE Santa Clara, California and Herzliya, Israel – July 24, 2017 – Nyotron announced today that it has closed a new $21 million financing round led by US-based investors and including all existing investors. The financing was significantly oversubscribed and positions the company to dramatically increase worldwide sales and marketing activities and to expand its current offerings of Nyotron’s innovative endpoint cyber security solution. Nyotron also announced the appointment of Peter Stewart to Chief Executive Officer. Mr. Stewart, who also is participating in this round, has held several important executive positions at McAfee and is the former Chief Executive Officer of TraceSecurity. Nir Gaist, founder of Nyotron and creator of the flagship product PARANOID, will
Continue reading "Nyotron takes in $21 mln"

Ironhack snags $3 mln

Ironhack, a coding and web design bootcamp with campuses in Madrid, Barcelona, Paris and Miami, has raised $3 million in funding. JME Venture Capital led the round. Source: Press Release

Ride-hailing firm Grab to get $2.5 billion as firms pump funds into SE Asia startups: Reuters

Ride-hailing firm Grab expects to raise $2.5 billion to spend extending its lead over Uber Technologies Inc [UBER.UL] and expanding into financial services, in the latest injection of funds into Southeast Asia’s burgeoning tech scene. Chinese peer Didi Chuxing and Japan’s SoftBank Group Corp (9984.T) will contribute most of the money, which a person close to the Singapore-based firm said would value it at $6 billion. The investment would be the latest in a Southeast Asian tech startup as major companies seek growth in the region’s huge developing economies with young, tech-savvy demographics. Chinese social media firm Tencent Holdings Ltd (0700.HK) put up to $150 million into Grab’s Indonesian peer Go-Jek, sources said this month, while in June, Alibaba Group Holding Ltd (BABA.N) spent an additional $1 billion to raise its stake in Singapore-based e-tailer Lazada. Grab’s fresh fundraising is “a real endorsement of the
Continue reading "Ride-hailing firm Grab to get $2.5 billion as firms pump funds into SE Asia startups: Reuters"

Allegro Ophthalmics scores $10.7 mln

Allegro Ophthalmics LLC, a biotech company focused on treating vitreoretinal diseases, has secured $10.7 million in funding. The investors were not named. PRESS RELEASE SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–Allegro Ophthalmics, LLC today announced the completion of a private round of equity financing for $10.7 million. With this infusion of capital, the company is strongly positioned to reach future corporate milestones. Allegro is a biotechnology company focused on the development of novel therapies to treat vitreoretinal diseases. The company’s lead drug candidate, Luminate®, has successfully met the endpoints for two Phase 2 monotherapy studies for the treatment of diabetic macular edema (DME) and vitreomacular traction (VMT). In addition, topline results of its Phase 2, Stage 2 DME clinical trial in which Luminate is being evaluated in combination and as an adjunctive therapy with anti-VEGFs will soon be announced. “The additional capital positions us well to complete multiple Phase
Continue reading "Allegro Ophthalmics scores $10.7 mln"